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Abstract 
Bone infection is a feared complication following surgery or trauma that remains as an 
extremely difficult disease to deal with. So far, the outcome of therapy could be 
improved with the design of 3D implants, which combine the merits of osseous 
regeneration and local multidrug therapy so as to avoid bacterial growth, drug resistance 
and the feared side effects. Herein, hierarchical 3D multidrug scaffolds based on 
nanocomposite bioceramic and polyvinyl alcohol (PVA) prepared by rapid prototyping 
with an external coating of gelatin-glutaraldehyde (Gel-Glu) have been fabricated. 
These 3D scaffolds contain three antimicrobial agents (rifampin, levofloxacin and 
vancomycin), which have been localized in different compartments of the scaffold to 
obtain different release kinetics and more effective combined therapy. Levofloxacin was 
loaded into the mesopores of nanocomposite bioceramic part, vancomycin was localized 
into PVA biopolymer part and rifampin was loaded in the external coating of Gel-Glu. 
The obtained results show an early and fast release of rifampin followed by sustained 
and prolonged release of vancomycin and levofloxacin, respectively, which are mainly 
governed by the progressive in vitro degradability rate of these scaffolds. This 
combined therapy is able to destroy Gram-positive and Gram-negative bacteria biofilms 
as well as inhibit the bacteria growth; in addition, these multifunctional scaffolds exhibit 
excellent bioactivity as well as good biocompatibility with complete cell colonization of 
preosteoblast in the entire surface, ensuring good bone regeneration. These findings 
suggest that these hierarchical 3D multidrug scaffolds are promising candidates as 
platforms for local bone infection therapy. 
 
Keywords: Multidrug 3D scaffold, combined therapy, biofilm, Gram-positive bacteria, 
Gran-negative bacteria and sequential antimicrobial delivery. 
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1. Introduction 
Bone infection is a potentially devastating complication with important clinical and 
socio-economic implications [1-3]. It is described as an inflammatory process that leads 
to bone destruction (osteolysis) usually caused by an underlying microbial infection, 
mainly by Staphylococcus aureus bacteria [4,5]. Conventional treatments, involving 
systemic antibiotic administration [6], surgery and implant removal [7,8], have 
important limitations and significant repercussions for the quality life of the patients 
such as, high side effects [9], prolonged hospital stays, additional surgical interventions 
[10], and even, high morbidity rate [11]. The main reason for the failure of these 
conventional treatments is the ability of bacteria to develop a biofilm [1-4]. Biofilms are 
described as communities of microorganisms that grow attached to a surface or 
interphase and embedded in a self-produced extracellular matrix [12].  Biofilm 
development is one of the most common processes that bacteria accomplish in a 
cooperative manner. Inside the biofilm, bacteria  grow protected from environmental  
stresses and resist antibiotics, disinfectants, phagocytosis and other components of the 
innate and adaptive immune and inflammatory defense system of the host giving as a 
consequence failure of the antibiotic treatment [13]. 
Currently, the nanotechnology field has emerged as a powerful tool to combat the 
infection process [14-16]. In this sense the development of novel multifunctional 3D 
scaffolds based on nanostructured materials to not only clear the infection but to also 
contribute to subsequent bone regeneration would be a very good alternative to 
conventional therapies [17-23]. The local antimicrobial administration will minimize 
side effects and risk of overdose, as well as to improve the bioavailability of the drug 
with the appropriate therapeutic concentration effectively reaching the target site [24]. 
Moreover, the possibility to achieve a combined therapy with different antimicrobial 
agents would be needed for a more efficient treatment of bone infection [25]. In this 
sense, an initial fast release of an antibiofilm drug to be able to destroy the biofilm 
capsule and subsequently more sustained and prolonged release of the different 
antibiotics would be desired [26]. 
Recently, a nanocomposite bioceramic (MGHA), formed by particles of nanocrystalline 
apatite embedded into amorphous mesoporous bioactive glass in the SiO2–P2O5–CaO 
system, has been reported. Due to the synergy of the features of its two components, 
including (i) ordered mesoporous arrangement with pores of 8 nm, (ii) high surface area 
and pore volume, (iii) high bioactivity, (iv) presence of nanocrystalline apatite particles 
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homogeneously distributed, and (v) improved in vitro biocompatibility, this 
nanocomposite material is an excellent candidate for bone tissue engineering and local 
drug delivery [27-30]. Concerning the fabrication processes to obtain scaffolds, 3D 
plotting techniques (also called direct writing or printing) have been widely developed 
to prepare porous scaffolds in recent years [31]. In this sense, recently, hierarchical 
meso-macro 3D porous scaffolds have been fabricated by a combination of a single-step 
sol–gel route in the presence of a surfactant as the mesostructure directing agent and a 
biomacromolecular polymer (methylcellulose) as the macrostructure template followed 
by rapid prototyping technique with a high potential in bone tissue engineering [32,33].  
However, this methodology for preparing scaffolds containing different antimicrobial 
agent is inconvenient, because of the need for methylcellulose and the additional 
sintering procedure.  
Currently, the fabrication of composite scaffolds based on bioceramic-polymer mixture 
has allowed improvement of their properties due to the synergy of the features of their 
components being widely used for different applications [34,35]. Therefore, the 
incorporation of biocompatible polymer have enhanced the mechanical properties of 
scaffolds by using room temperature in the process, which offers the possibility to 
incorporate drugs for the subsequently controlled release [36]. In this case, polyvinyl 
alcohol (PVA) is selected because it is generally biocompatible, degradable and water 
soluble so toxic solvents do not need to be used in the preparation. In addition, PVA can 
be cross-linked to improve its crystallinity and to control its dissolution by a simple heat 
treatment at low temperature [37]. A previous study has shown that mixing mesoporous 
glasses powders with an aqueous PVA solution to form an injectable paste is very 
efficient to fabricate 3D scaffolds. In addition, several studies have shown that gelatin-
glutaraldehyde (Gel-Glu) coatings onto the 3D scaffolds could improve both, its 
mechanical properties as well as the early and fast release of a drug depending on the 
cross-linking degree of the gelatin [38-40]. 
The present study is focused in finding an adequate therapeutic solution for the 
treatment of bone infection by the design of hierarchical 3D multidrug scaffolds based 
on nanocomposite bioceramic, highly bioactive and biocompatible, with PVA polymer. 
These structures must be able to incorporate different drugs in various compartments for 
combined therapy, which allows to eradicate the bacterial biofilm and thus, to 
completely eliminate the bone infection. For antimicrobial therapy, currently there are 
many antimicrobial agents and combinations [1,7]. It is important to assure the maxima 
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antimicrobial efficacy by sustained and prolonged administration in the time. 
Levofloxacin (LEV) is successfully used in clinical record in the treatment of bone 
infection due to ability to penetrate into trabecular and cortical bone, minimizing the 
risk of resistance selection [41,42]. Moreover, LEV exhibits a sustained release in 
mesoporous matrices due to the strong interaction with the silanol groups [30]. On the 
other hand, vancomycin (VAN) is widely used during the prophylaxis and postoperative 
surgery for prevention and treatment of bone infection [7]. VAN is described as a 
tricyclic glycopeptide antibiotic commonly used for treatment of severe infections 
caused by Gram-positive bacteria and especially indicated for methicillin-resistant S. 
aureus (MRSA), penicillin-resistant pneumococci, or patients allergic to penicillins and 
cephalosporins [43-45]. Moreover, due to its hydrophilic character exhibits sustained 
and prolonged release in polymeric systems [46,47]. Finally, rifampin (RIF) is an 
antibiofilm antibiotic, which is able to attack and destroy the Staphylococci in biofilm. 
RIF must always combined with another antibiotic because bacteria can develop 
resistance very rapidly when it is used as a monotherapy [48]. In this sense, this drug 
has been reported to present a synergy when it is administrated with other compounds 
such as levofloxacin and vancomycin [49]. 
Herein, the present study proposes a 3D multifunctional scaffold as a novel drug 
delivery system for treatment of bone infection and bone regeneration. This 3D system 
will be constituted by a mixture of nanocomposite MGHA and PVA containing 
different antimicrobial agents in different compartment to achieve different release 
kinetics. The 3D multifunctional scaffolds will be fabricated by rapid prototyping 
technique using a paste formed by aqueous mixture of calcined MGHA powder and 
PVA. Previous to scaffolds fabrication, both LEV and VAN will be incorporated into 
the mesopore structure and polymer matrix, respectively. Finally, this 3D scaffolds will 
be coated by a gelatin/glutaraldehyde layer containing RIF to obtain an early and fast 
release of this antibiofilm agent. In vitro degradability assays in simulated body fluid 
and biocompatibility assays in presence of preosteoblast have been performed in order 
to study the bone regeneration capability of these scaffolds. Moreover, antimicrobial 
tests to study the effectiveness on 3D multifunctional scaffolds against Staphylococcus 
and Escherichia biofilms have been also reported. Fig.1 displays the schematic design 
of multidrug 3D scaffold as well as the processing of fabrication. 
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2. Materials and methods  
2.1. Synthesis of mesoporous ceramic powder containing levofloxacin  
Highly mesostructured nanocomposite MGHA formed by mesoporous glass matrix with 
nanoparticles of apatite embedded inside of the matrix has been synthesized through the 
evaporation-induced self-assembly (EISA) method [50] using a non-ionic surfactant, 
Pluronic F127 (BASF) as structure directing agent, and tetraethyl orthosilicate (TEOS, 
98%, Sigma–Aldrich), triethyl phosphate (TEP, 99.8%, Sigma–Aldrich), and calcium 
chloride (CaCl2·4H2O, 99%, Sigma–Aldrich) as SiO2, P2O5, and CaO sources, 
respectively [27]. Briefly, in a typical synthesis, 19.5 g of F127 are dissolved in 168.6 
mL of absolute ethanol (99.5%, Panreac) with 12.8 mL of 1.0 M HCl (prepared from 
37% HCl, Panreac) solution and 19.4 mL of Milli-Q water. Aferwards, the appropriate 
amounts of tetraethyl orthosilicate (TEOS, 98%, Sigma-Aldrich), triethyl phosphate 
(TEP, 99.8%, Sigma-Aldrich), and calcium chloride (CaCl2·4H2O, 99%, Sigma-
Aldrich) as SiO2, P2O5 and CaO sources, respectively, were added in 1 h intervals under 
continuous stirring for 4 h at 40°C and subsequently maintained under static conditions 
at the same temperature overnight. The resulting sols were cast in Petri dishes (9 cm 
diameter) to undergo the EISA method at 30 °C. The gelation process occurred after 3 
days, and the gels were aged for 7 days in the Petri dishes at 30 °C. Finally, the dried 
gels were removed as homogeneous and transparent membranes (several hundreds of 
micrometers thick) and calcined at 700 °C during 6 h to remove the surfactant, organics 
residue, and chloride ions. Once calcined, powder MGHA material was sieved to a size 
lower than 40 µm for the scaffold preparation [51]. LEV loading was carried out by 
impregnation method, soaking the powder MGHA material in an ethanolic solution 
containing 5.7 mg/ml of levofloxacin and incubated during 24 h in dark and orbital 
stirring conditions. The ratio powder and impregnation solution was 1g per 100 ml of 
dissolution. Then, the samples were filtered, gently washed with absolute ethanol, and 
denoted as MGLEV. 
2.2. Fabrication of 3D-scaffolds containing levofloxacin and vancomycin by Rapid 
Prototyping  
3D multidrug scaffolds were prepared by rapid prototyping via direct-write assembly of 
precursor slurry using an EnvisionTEC GmbH 3-D Bioplotter™ device [28]. The 
injectable slurry is formed by mixture of powder MGLEV with PVA by mixing 6 g of 
mesoporous powder after levofloxacin impregnation with 0.9 g of an aqueous PVA 
solution containing 34 mg of vancomycin. The obtained scaffolds were denoted as 
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MGLEV-PVAVAN. With the purpose of comparing, 3D MG-PVA scaffolds without drugs 
and containing just one drug were fabricated in the same conditions as follows: MG-
PVA, MGLEV-PVA, MG-PVAVAN.  
Cylindrical scaffolds of 1 cm diameter x 4 mm height were fabricated layer-by-layer by 
direct ink deposition over a plate at 40 ºC of temperature. The final ink with the right 
rheological properties was then placed into a polyethylene cartridge (with a Luer-Lock 
adapter) and fixed to a smooth flow tapered dispensing tip for highly viscous materials 
with an internal diameter of 0.6 mm (EFD-Nordson). Each layer was pre-designed 
showing a 90º rotation with respect to the previous. To obtain the best results, the 
dispensing speed and pressure were slightly modified from the starting machine 
parameters during the dispensing process for each scaffold. The scaffold hardening 
process occurred by solvent evaporation and the pieces were left to dry at 40 ºC for 3 
days (see Fig.1) [28].  
2.3. Coated 3D-scaffolds with Gelatin-Glutaraldehyde containing rifampin 
For achieving an early and fast release of the antibiofilm antibiotic, an additional 
coating of mixture Gel-Glu containing RIF was applied by using the dip-coating 
technique onto 3D scaffolds. This biopolymer coating was chosen because is approved 
by the US Food and Drug Administration (FDA). As a method of introducing this 
antibiotic in gelatin has not been described, several test were carried out to find the best 
conditions and proportions of reactants for and homogeneous coating of the scaffold and 
an early and fast release of the drug. For this purpose, two different gelatine 
concentrations in water (1.2 and 2.4% (w/v)) were prepared and the RIF was dissolved 
in both solutions at a concentration of 0.6 mg/ml. After that, both solution were mixed 
with a solution 0.5% (v/v) of glutaraldehyde in stirring conditions during 1 h at 20 ºC. 
Gelatine was, previously, cross-linked with glutaraldehyde to reduce its solubility in 
water [52]. After that, 3D scaffolds were soaked in such biopolymer solutions, extracted 
and dried at room temperature (see Fig.1). These samples were denoted as 
GRIFMGLEVPVAVAN. 
2.4 Characterization  
Structural, textural and chemical characterization was carried out by using different 
techniques. X-Ray diffraction (XRD) experiments were performed on a Philips X’Pert 
diffractometer MPD (Eindhoven, The Netherlands) equipped with a support for thin 
films (grazing incidence) and CuKα radiation (40 kV, 20 mA). Textural properties were 
determined by N2 adsorption porosimetry using a Micromeritics ASAP2020 analyzer 
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(Norcross, USA). Surface area was determined utilizing the multipoint Bruneauer-
Emmett-Teller method included the software. Chemical composition was determined by 
elemental analysis (C, H, N) carried out on a LECO CHNS-932 microanalyzer (Saint 
Joseph, Michigan, USA) and Fourier Transformed Infrared spectroscopy (FTIR) in a 
Thermo Nicolet Nexus spectrophotometer (Thermo Scientific, USA) equipped with the 
Goldengate accessory for Attenuated Total Reflection (ATR). Microstructure of the 
scaffold was examined by scanning electron microscopy (SEM) using a field emission 
microscope JEOL JSM-6335F (Tokyo, Japan) at an acceleration voltage of 10 kV.  
2.5. In vitro degradability assay in simulated body fluid  
With the aim of evaluating the in vitro degradation as well as the bioactivity level of 
GRIFMGLEVPVAVAN 3D scaffolds were immersed at different time periods for 30 days 
in a total volume of 50 ml of simulated body fluid (SBF) under continuous stirring (100 
rpm) [53]. After that, 3D scaffolds were removed and gently washed with Milli-Q 
water. The variation of calcium concentration and pH in the SBF during the experiment 
was performed by ion selective electrode technique in an Ilyte system (Na+, K+, Ca2+, 
pH). The surface changes onto the 3D scaffolds during the degradability test were 
evaluated by scanning electron microcopy (SEM) after different times. Moreover, the 
changes occurred onto scaffold surface as a function of soaking time in SBF were 
studied by transmission electron microscopy (TEM) in a JEOL 3000 FEG electron 
microscope fitted with a double tilting goniometer stage (45°) and with an Oxford LINK 
EDS analyzer. 
 
2.6. In vitro Drug release Studies 
The in vitro release of different drugs from 3D GRIFMGLEVPVAVAN scaffolds were 
carried out by different techniques, previously checking the not interaction between 
them. Moreover, the release kinetics of each drug has been studied separately to verify 
the non-competitiveness between drugs. For these purposes it has been studied the 
release profiles in the scaffolds MGLEVPVAVAN, MGPVAVAN, MGLEVPVA and GRIF-
MG-PVAVAN. The obtained results show that the release profiles are identical alone and 
in presence of two or more drugs.  
In this sense, the in vitro release was carried by soaking individually each 3D scaffold in 
25 ml of PBS (Phosphate Buffer Saline). Then, they were introduced into an Incubator-
Shaker, where they were smoothly stirred at 100 rpm and at 37 °C. For the LEV release, 
since it is a fluorescent molecule, its determination was performed using a 
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spectrofluorimeter BiotekPowerwave XS, version 1.00.14 of the Gen5 program, with a 
ƛexcitation = 292 nm and ƛemmision = 494 nm [30]. In vitro VAN release over time was 
determined by High Performance Liquid Chromatography (HPLC) using a 1260 Infinity 
HPLC system (Agilent) and UV-Vis analysis at 290 nm at different times [46]. It has 
been proved that no interferences appear between VAN and LEV in HPLC. Finally, to 
determine the in vitro RIF release UV-Vis spectroscopy technique was used, since it 
exhibits a band at 474 nm in UV-Vis which was chosen because it does not interfere 
with the band of VAN. Determination of the concentration of RIF over time was 
performed by using Helios Zeta UV-VIS spectrophotometer at 474 nm at different times 
[54]. 
2.7. Antimicrobial activity of 3D scaffolds 
Prior to the bacterial tests, the samples were sterilized by UV-light radiation during 10 
min in both sides. The effectiveness of these multidrug 3D systems against 
Staphylococci in biofilm has been determined. Previously, biofilms of S. aureus was 
developed and incubated onto cover glass disks. For this purpose, cover glass disks was 
suspended in a bacteria solution of 108 bacteria per ml during 48 h at 37 ºC and orbital 
stirring at 100 rpm. In this case the medium used was 66% TSB + 0.2% glucose 
medium to promote robust biofilm formation. After that, the cover glass disks 
containing biofilm were localized onto six well culture plates (CULTEK) in 6 ml of new 
medium. Then, multidrug 3D scaffolds were submerged avoiding the direct contact with 
biofilm coated glass disk. After different times of incubation, the glass-disk were 
washed three times with sterile PBS, stained with a 3 µl/ml of Live/Dead® Bacterial 
Viability Kit (BacklightTM) and 5 µm/ml calcofluor solution to specifically determine 
the biofilm formation, staining the mucopolysaccharides of the biofilm (extracellular 
matrix in blue) [55]. Both reactants were incubated for 15 min at room temperature. 
Biofilm formation was examined using a in an Olympus FV1200 confocal microscope. 
In order to check the strategy proposed by using multidrug systems, scaffolds only 
containing only VAN and LEV and both were also evaluated in order to evaluate the 
effectiveness of combined therapy. 
Parallel, the effectiveness of these 3D multidrug systems have been also carried out 
against gram negative bacteria as Escherichia coli (E. coli). Similar experiments were 
carried out for E. coli biofilm. Previously, E. coli biofilms were formed onto cover glass 
disks by inoculated 108 per ml bacteria solution during 48 h at 37 ºC and orbital stirring 
at 100 rpm. After different times of incubation, the glass-disk were washed three times 
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with sterile PBS, stained with Live/Dead® Bacterial Viability Kit (BacklightTM) and 
calcofluor in similar way that S. aureus test and examined in confocal microscope.  
In addition, the determination of number of colony-forming units (CFU) present in each 
biofilm (Gram-positive and gram-negative) before and after treatment with 3D 
multidrug systems was carried out. Each biofilm coated glass disk was previously 
sonicated during 15 minutes in 6 ml of sterile PBS to remove all bacteria from biofilm. 
After, that 100 µl of the bacteria suspension was cultivated on Tryptic Soy Agar (TSA) 
(Sigma Aldrich, USA) plates, followed by incubation at 37 oC overnight. Then, CFUs 
were counted and represented as Log [CFU]. Six replicated were done for each 3D 
multidrug system at different times (1, 6 and 24 h). 
2.8. In vitro biocompatibility studies: MC3T3-E1 preosteoblast culture  
Previous to in vitro assays with osteoblast cells, all samples were sterilized by UV 
radiation during 10 min. Cytotoxicity, cell morphology, mitochondrial activity and cell 
differentiation studies were carried out by utilizing MC3T3-E1 pre-osteoblasts (mouse 
osteoblastic cells able to differentiate to osteoblast or osteocytes) cultured on the 3D-
scaffolds of different compositions. For this purpose, the cells were cultured in complete 
medium Eagle medium alpha modified by Dulbecco (α DMEM) supplemented with 2 
mM glutamine, 100 U ml-1 penicillin, 100 g·ml-1 streptomycin and fetal bovine serum 
(FBS) at 10% at 37 ºC under atmosphere conditions of 95% humidity and 5% CO2. 
MC3T3-E1 cells in a concentration of 2.5·105 cells/mL in complete medium were 
cultured on the 3D-scaffolds previously placed in 24-well plates and cultured in 5% 
CO2 and 95% humidity atmosphere at 37 ºC during different times. Control samples 
corresponds to empty positions where the same quantity of cells was cultured. 
Citotoxicity Test – LDH 
Activity of the lactate dehydrogenase enzyme (LDH) was determined in the culture 
medium in contact with the scaffolds after 1 and 7 days of incubation. Activity of LDH 
released by the MC3T3-E1 cells is directly related to the rupture of the plasmatic 
membrane (cell death) that, when broken, releases all organelles and enzymes present in 
the cytoplasm. Measurements were performed by using a commercial kit (Spinreact) at 
340 nm with a UV-Visible spectrophotometer Unicam UV-500.  
Cell morphology studies – SEM 
For these studies, adherent cells of different samples were fixed with glutaraldehyde 
(2.5% in buffer solution, PBS) for 45 min. Afterwards, all the samples were gradually 
dehydrated through the progressive replacement of water with a serie of ethanol 
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solutions (30%, 50%, 70% and 90%) for 30 min with a final dehydration in absolute 
ethanol for 60 min. Later, samples were introduced into a vacuum oven at 40°C for 
7days. After this time, samples were stick onto cupper holder and finally metallized 
with gold in a metallization device EMS150R-S. Study of the cell morphology on 
different scaffolds was performed by using SEM in a JEOL 3565F. 
Cell morphology and colonization studies – Confocal microscope 
Fluorescence microscopy was performed with a confocal laser scanning microscope 
OLYMPUS FV1200 (OLYMPUS, Tokyo, Japan), using a 60x FLUOR water dipping 
lens (NA=1.0). The images were prepared for analysis using Software 3D Imaris to 
project a single 2D image from the multiple Z sections by using an algorithm that 
displays the maximum value of the pixel of each Z slice of 1 µm of depth. The resulting 
projection was then converted to a TIF file using this software. In the images, DAPI and 
Atto 565–phalloidin were visualized in blue and red, respectively. The reflection of the 
scaffold material was visualized in green. The dyeing process was performed using the 
methodology described elsewhere [56].  
Mitochondrial Activity – MTT 
For evaluating cell mitochondrial activity of living cells on the different scaffolds as 
well as its surroundings after 1 an 7 days of incubation the MTT method was employed. 
This method is based in the reduction of 3-(4,5-dimethylazol-2-yl)-2,5-
diphenyltetrazolium (yellow) to blue formazan. This measurement was used in terms of 
cell proliferation as described in previous works. For this purpose, culture medias were 
substituted with 1 ml of DMEM and 125 µL of 0.012 g·ml-1 MTT solution in PBS. 
Samples were incubated for 4 h at 37°C and 5% CO2 in dark conditions. Then, media 
was removed and 500 µL of HCl-isopropanol solution 0.4 M. Finally, absorbance at 570 
nm was measured by using a Helios Zeta UV-VIS spectrophotometer.  
Alkaline Phosphatase Activity – ALP 
ALP of the cells growing onto the scaffolds was utilized as marker of cellular 
differentiation in the evaluation of the phenotype expression of osteoblasts. ALP was 
measured employing the Reddi-Huggins method based in the hydrolysis of p-
nitrophenylphosphate to p-nitrophenol. For this purpose, MTC3T3-E1 pre-osteoblastic 
cells (2.5·105 cells·ml-1) were cultured directly on top of the scaffolds in a 24-well plate 
and incubated under standard culture conditions using media supplemented with β-
glycerolphosphate (50 mg·ml-1) and L-ascorbic acid (10 mM). For evaluating ALP of 
both, scaffolds and its surroundings, after 7 days of incubation, each scaffold was 
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transferred to a new well. The measurements have been normalized with respect the 
amount of protein total determined by Bradford colorimetric method.  
Mineralization test  
Matrix mineralization was measured by alizarin red staining after cell incubation with 
GRIFMGLEVPVAVAN scaffolds for 10 days, as described [57]. Since the samples contain 
calcium in its composition this study has been conducted on the well. Stain was 
dissolved with 10% cetylpyridinum chloride in 10 mM sodium phosphate, pH 7, and 
measuring absorbance at 620 nm. Moreover, the mineralization process has been 
studied by a deep surface characterization with XRD with and also without presence of 
preosteoblast cells. The high surface roughness of the samples, when compared with a 
standard powder XRD preparation, has hampered the XRD measures giving rise to a 
poor signal-to-noise ratio. 
 
Statistical Analysis 
Data was expressed as average/mean ± standard deviation in three experiments. Statistic 
analysis was performed by using the software Statistical Package for the Social Sciences 
(SPSS) version 11.5. Statistical comparatives were carried out through variance analysis 
(ANOVA). Scheff proof was utilized for the post hoc evaluation of the differences 
among groups. In all statistical evaluations, p<0.05 was considered as statistically 
significant. 
 
3. Results and Discussion  
All scaffolds were structural, chemical and morphological characterized by different 
techniques. Firstly, the structural characterization of the MGHA powder (before and 
after LEV loading) and different 3D scaffolds (MGPVA, MGLEVPVA, MGPVAVAN, 
MGLEVPVAVAN and GRIFMGLEVPVAVAN) was carried out by XRD to observe both, its 
mesoporous arrangement and the presence of nanocrystalline hydroxyapatite embedded 
into glassy matrix, respectively. Fig.2 displays XRD patterns corresponding to 
MGHALEV powder and 3D scaffolds before and after coating (MGLEVPVAVAN and 
GRIFMGLEVPVAVAN). Low angle XRD pattern (left) shows a well-defined diffraction 
maximum at 2θ = 0.86 degree and wide maxima around 2θ = 1.43 and 1.67 degree, 
which could be indexed as 10, 11, and 20 reflections of a 2D-hexagonal structure with 
p6mm plane group, based on TEM study (see below). Wide angle XRD pattern (right) 
reveals the presence of nanocrystalline apatite phase exhibiting (002), (211) and (310) 
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reflections. These results highlight the fact that both prototyping scaffolding and 
posterior dip-coated processes do not affect to the structural order of the material, 
maintaining the 2D-hexagonal structure and nanocrystallinity of the apatite phase 
present in them. Moreover, the presence of different antibiotics on the scaffolds do also 
not affect to the mesoporous structure and nanocrystallinity of the nanocomposite 
mesoporous material. 
Textural properties revealed a significant decrease in both, specific surface area and 
total pore volume, before and after the LEV drug loading, respectively. It is reported in 
the literature that the decreasing in the values of specific surface area, total pore volume 
and pore diameter after drug loading process is related to the confinement of the drug 
into the mesoporous structure [58]. Table 1 shows the percentages (%) of each antibiotic 
present in each scaffold with respect of the weight of the scaffold and the variation of 
their textural properties after impregnation process, conformed by RP technique and 
dip-coated process, respectively. 
Concerning to the yielding of the drug loading process, it was determined by 
combination of elemental chemical analyses and TG studies. The percent of nitrogen, 
carbon and hydrogen for all samples obtained by elemental analysis have been collected 
in the Table S1 in the supporting information. Taking into account that both MGHA 
powder and PVA polymer do not content nitrogen in the composition, then LEV and 
VAN were determined by calculation of the % of nitrogen in the sample. Concerning 
LEV amount, the % of nitrogen of MGHA powder after impregnation process and 
scaffolding remains unchanged with a value of 3%. Although a priori, this percentage 
would seem low, it is within the normal range of loading of a drug by the impregnation 
method [59]. The amount of VAN was determined in presence or not of VAN obtaining 
a value of 1.8 %. Finally, the amount of rifampin was determined by two different 
methods by TG analyses (data not shown) on the coating scraped from the scaffolds and 
in presence of not of antibiotic by showing a percent of 2.5 %. This percent was 
confirmed by an indirect method, by total dissolution of RIF coating in acidic medium 
and determination by UV-Vis at 474 nm. 
Morphology study of the different 3D scaffolds was performed by SEM. Before dip-
coating process, the MGLEVPVAVAN scaffolds exhibit a very high porosity in both, 
surface and inner structure. Giant macropores of about 1 mm can be observed as well as 
a regular and high porosity all over and in the scaffold (Fig.3A). High magnification 
shows the presence of mesopores of around 50 µm (Fig.3B) and a similar view is 
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observed in the cross-section (CS) (see supporting information Fig.S1), which indicated 
the high rate of interconnectivity. A detail of the surface shows a smooth polymeric 
surface with incrustations of MGHA ceramic material (Fig.3C and 3D). It is important 
to keep in mind that free drug 3D-scaffolds exhibit similar morphological features, 
showing that the incorporation of different antibiotics does not affect to the morphology 
of the scaffold. In addition, TEM image and FT diagram (Fig.3E) display a mesoporous 
arrangement in the 2D hexagonal structure, showing the 3D hierarchical structure of 
MGLEVPVAVAN scaffold.  
In order to obtain an early release of RIF antibiofilm, MGLEVPVAVAN were coated by 
dip-coating method with a gelatin-glutaraldehyde mixture containing a RIF solution. In 
this sense, this external coating should, once delivered, break the biofilm capsule 
allowing the VAN and LEV activity. SEM studies the 3D scaffolds after coating 
containing rifampin are shown in Fig.4. The obtained results show that after coating the 
macropores corresponding to 1 mm are obstructed by a layer of thickness of 5 µm.  
In vitro degradability assay in SBF of GRIFMGLEVPVAVAN was performed at different 
key times (Fig.5). After 1 h of incubation, SEM image displays the total dissolution of 
the coating leaving empty pores 1 mm. In addition, the in vitro degradability assays in 
SBF were performed during long periods of incubation at 15 and 30 days. The obtained 
results show a partial degradation of scaffold with the appearance of pores on the 
scaffolds surfaces. Higher magnification micrographs show also a typical layer of 
hydroxyapatite formed, which is identified by the needle-like particles observed all over 
the surface of the scaffolds indicating a high level of bioactivity. Parameters such as pH 
and [Ca2+] were also monitored during this experiment, showing as initial increasing of 
calcium content until 7 days followed of a decreasing until 30 days which indicates the 
bioactivity process (see supporting information Fig.S2). To confirm this bioactive 
process, TEM studies of the scrapped surfaces were carried out and collected in Fig. 6. 
The obtained results confirm a formation of a nanocrystalline hydroxyapatite layer onto 
the surfaces of 3D multifunctional scaffold after 7 days in SBF.  
In vitro release tests of different 3D scaffolds containing drugs were carried out in PBS 
at pH 7.4 and 37 ºC. Fig.7 shows the different LEV, VAN and RIF release profiles from 
the GRIFMGLEVPVAVAN scaffolds. In the case of VAN and LEV, the release profiles are 
more sustained and prolonged in time in comparison with the RIF release, which is 
characterized by a fast release in just one hour, according to in vitro degradability tests. 
Fig.S3 displays the dosages corresponding to GRIFMGLEVPVAVAN sample after 1, 6 and 
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24 h of incubation. The minimum inhibitory concentration (MIC) of each antibiotic is 
0.5 µg/ml [60,61] for RIF and 0.5-1 µg/ml [62] for LEV and VAN. Since the release 
dosage from GRIFMGLEVPVAVAN scaffolds displays an initial effective dosage formed by 
three antibiotics followed of an effective and sustained dosage for long periods of time 
(> 10 days) for LEV and VAN.  
For porous and polymer matrices, it has been reported that drug release can be mediated 
by diffusion, erosion/degradation and swelling followed by diffusion. Although some 
matrix degradation is involved, under perfect sink conditions, the main driving force for 
drug delivery out of the mesoporous matrices is pore diffusion/convection, which can be 
fitted to first order kinetics. Additional parameters such as drug-carrier and host-guest 
interactions are key factors to dictate drug release profiles. Drug molecules could 
directly interact with the matrix, in this case, the mesoporous material, the PVA 
polymer and the Gel-Glu mixture retarding their release. The association and 
dissociation processes are assumed to be reversible. Furthermore, in general, the 
reversible association of a drug molecule with a carrier is assumed to follow first order 
kinetics. Therefore, the theoretical model adopted in this work considers first-order 
diﬀusion/convection and drug association/dissociation. Concretely, drug release patterns 
correspond to fast diﬀusion/convection but slow association/dissociation. This leads to a 
decoupling of drug association/dissociation from drug diﬀusion/convection: the fast 
release of initially free drug molecules via diﬀusion/convection and the slow release of 
initially bound drug molecules that is dictated by the dissociation process. Accordingly, 
two first order kinetics or two exponential release mechanisms can be described as 
follows [63].  
       Eq: 1 
Where Qt is the cumulative drug release a time t; Q0 is the initial amount of drug; ks is 
the rate constant of diffusion/convection; and kon and koff are the rate constants of 
association and dissociation respectively. The free energy difference between the free 
and bound states, ∆G, determines the amounts of initially free and bound drug and can 
be calculated by the following equation 2: 
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 Eq: 2 
Where kB is Boltzmann’s constant and T is the absolute temperature (assumed to be 
310K). In this study, therefore, three parameters, ∆G (instead of kon), ks and koff were 
used to describe the cumulative drug release from the fabricated scaffolds. Fitting 
experimental release patterns to eq. 1 allowed the determination of the experimental 
values for ks, kon and koff. Then, ∆G was calculated using eq. 2. The experimental results 
are summarized in Table 2. 
Drug release profiles can be classified into four distinct categories (A-D). The 
categories are based on the magnitude of the initial burst release, the extent of the 
release and the steady-state release kinetics folowing the burst release. The burst release 
is described as the initial release before reaching the steady-state. In types A and B, the 
initial burst release is followed by little additional release. The release profile in type C 
is similar to that in type A in terms of initial burst, but the burst release is followed by a 
steady-state release of the remaining drug. Finally, type D exhibits a low initial burst 
release followed by a steady-state release until most of the loaded drug is released 
[64,65]. 
From the data of the Table 2, kinetic profiles of the drugs can be classified. In the case 
of LEV release, ks>>koff wich indicates that difussion and convection are not neglected 
during the steady-state release. Accordingly, LEV release profile can be classified as 
type B, exhibiting a low initial burst release with steady-state release. 
RIF also presents ks>>koff, however, value of ∆G is higher, meaning rifampicin release 
profile belongs to type C kinetic release. Finally, VAN presents ks<koff with a very high 
value of ∆G, which indicates a high burst effect at the beginning of the release but a 
high interaction between the drug and the matrix (PVA) meaning a steady-state release 
corresponding to type A. 
Once determined release profiles, antimicrobial assays have been carried out to 
determine the effectiveness of these multidrug systems against S. aureus biofilms. 
These antimicrobial studies has been carried out for all scaffold containing one, or two 
or three drugs in order to determine the success of the proposed combined therapy. Fig.8 
displays the most representative results derived of the effects of MGLEVPVAVAN and 
GRIFMGLEVPVAVAN 3D scaffolds onto the preformed S. aureus biofilm by confocal 
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laser scanning microscopy (CLSM). Initially, the preformed biofilm shows a typical 
structure formed by colony live bacteria (green) covered by protective 
mucopolysaccharide matrix (blue). After 1 h of incubation with the different samples, 
notable differences are observed in presence or not of RIF. MGLEVPVAVAN containing 
both LEV and VAN is not able to destroy completely the biofilm, appearing even live 
bacteria colonies coated with its protective layer as it can observe in Fig.8. However, 
GRIFMGLEVPVAVAN scaffolds totally destroy the biofilm, observing colonial killed 
bacteria without the presence of protective layer of mucopolysaccharides. These results 
agree with in vitro drug kinetic assays (Fig.7), where a sudden release of all amount of 
RIF present on the scaffold was released together with a sustained release of both VAN 
and LEV in the first hour of incubation (Fig.S3), which it seems to be an effective 
strategy for the elimination of bacteria biofilm. After 24 h, the GRIFMGLEVPVAVAN 
scaffold shows complete destruction of biofilm appearing isolated fragments, while 
MGLEVPVAVAN scaffolds still exhibits bacteria colonies with protective covered, 
indicating no efficacy against biofilm. It is important to remark that after long time of 
exposure all scaffold containing one or two drugs showed a total destruction of studied 
biofilm. These results show that our multidrug systems formed by the combination of 
RIF, LEV and VAN together with the designed strategy designed are very effective for 
the total destruction of biofilm in the first 24 h of incubation, which is indicative of their 
antimicrobial efficient [66].  
In general the resulting biofilm in a common infection case may not be single species 
biofilm. Thus, the effectiveness of these multidrug systems has been also determined on 
gram-negative pathogenic as E. coli. Fig.9 shows the most significant results of E. coli 
biofilm after different times of incubation with GRIFMGLEVPVAVAN. At it can be 
observed, initially the effectiveness against Gram-negative biofilm is lower with respect 
to Gram-positive, due to after 1 h of incubation still appear small colonies of 20 µm, 
which are formed by live bacteria (green) coated with a protective matrix (blue). After 6 
and 24 h of incubation, the scenary is very similar to S. aureus a few scattering formed 
by small fragments of protective biolayer (blue), dead bacteria (red) and small amount 
of lived bacteria (green). 
In order to quantify the number of live bacteria present in each biofilm after of different 
treatments, CFU was determined. The results were summarized in the Fig.10. The 
obtained results shows notable differences in both 3D scaffolds, containing and not RIF. 
For MGLEVPVAVAN, the histogram evidences bacterial survival above 102 CFU after 24 
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h of incubation in both pathogens. It has been reported that a few live bacteria as 10-100 
CFU can cause an infection, which show the inefficient of this system [67]. On the 
contrary, the CFU analysis for the GRIFMGLEVPVAVAN systems  display a notable 
efficiency against both Gram-negative and Gram-positive bacteria, showing values 
below 10-100 CFU after 6 and 24 h of incubation, respectively. 
With the purpose of evaluating the biocompatibility of the fabricated 3D scaffolds for 
achieving bone regeneration, in vitro studies with MC3T3-E1 preosteoblast cells were 
carried out. The studies were performed on all scaffold (MGPVA, MGLEVPVAV and 
GRIF-MGLEVPVAVAN, to determine the influence of different component in the 
biocompatibility studies However, the most representative assays onto 
GRIFMGLEVPVAVAN are shown in this manuscript. Parameters such as cytotoxicity 
(related to LDH), proliferation (related to mitochondrial activity), cell morphology and 
cellular differentiation (related to ALP) were studied (Fig.11 and Fig.S4). As it can be 
observed in Fig.11, in LDH assay, control well and GRIFMGLEVPVAVAN scaffold do not 
present significant differences, which indicates a good level of biocompatibility. This 
fact reveals the non-delivery of “cytotoxic products” from the scaffold to the cell media 
and also that, the amount of delivered drug in this time (1 day) has not a cytotoxic effect 
for the cells and its surroundings (Fig.S4). Regarding the proliferation studies after 7 
and 15 days (MTT), results show an adequate proliferation on the scaffold and no 
significant differences observed with respect to the control well indicating a good cell 
colonization and proliferation on the scaffolds. Cellular differentiation studies at 7 days 
show a slight decreasing of ALP activity could be attributed to the presence of 
antibiotics in the media and it is an indicator of the influence of the antibiotics on the 
differentiation process. However, after 15 days (Fig.S4) any significant differences are 
observed in all scaffolds, which could be indicative of the initiation of remodeling 
process observed after in vitro studies in SBF (Fig.5 and Fig.6). Finally, mineralization 
studies have been carried out by alizarin test onto well plate and a deeper XRD study on 
the scaffold surfaces after 10 days in in vitro culture with and also without presence of 
preosteoblast cells. The obtained results are collected in Fig.12, showing no significant 
differences on the alizarin test between GRIFMGLEVPVAVAN scaffold and control. 
However, the XRD studies clearly show the mineralization process by formation of a 
nanocrystalline apatite phase on the surface of these scaffolds, whose crystallinity 
increases in the presence of preosteoblasts. 
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Cell morphology and cell colonization were studied by SEM and CLSM. Fig.13A 
shows a SEM micrograph corresponding to the GRIFMGLEVPVAVAN scaffolds after 7 
days of incubation showing extended cells in entered surface of scaffolds emitting 
filopodia as communication and anchoring elements. The cells colonizing all surface of 
scaffolds were visualized by staining (Fig.13B). Active cytoskeleton was stained with 
phalloidin and the nuclei with DAPI and cells were observed by confocal laser scanning 
microscopy. The image indicates that, after 7 days of culture, MC3T3-E1 cells have 
proliferated onto this scaffold, in agreement with the image obtained by SEM. In order 
to visualize those cells migrating upward, 200 sections of 1 µm thickness along Z axis 
were acquired and processed in single 2D images. In this case, the image shows an 
aggrupation of spread cells colonizing the pore walls of the scaffold, showing cells well-
developed with actine cytoskeleton organized into long parallel bundles, extending 
protrusions in the direction of migration. 
 
Conclusions 
A novel therapeutic solution for bone infection treatment based on 3D multifunctional 
scaffolds, which combines the merits of osseous regeneration and local multidrug 
delivery has been developed. The 3D multidrug scaffolds, containing rifampin, 
levofloxacin and vancomycin, have been designed by rapid prototyping of mixture of 
nanocomposite bioceramic and polyvinyl alcohol with an external coating of gelatin-
glutaraldehyde. The different antimicrobial agents have been localized in different 
compartments to achieve different release kinetics. These 3D multidrug scaffolds, 
exhibiting an early and fast release of rifampin followed by sustained and prolonged 
release of vancomycin and levofloxacin, are able to destroy Staphylococcus and 
Escherichia biofilms as well as inhibit bacteria growth in very short time periods. This 
new combined therapy approach involving the sequential delivery of antibiofilms with 
antibiotics constitutes an excellent and promising alternative for bone infection 
treatment. 
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Tables:  
Table 1: Data corresponding to the textural properties as surface area (SBET), pore 
volume (Vp) and pore diameter (Dp). Percent of PVA and different antimicrobial agents 
presents in the different scaffolds. In the table is also shown the MGHA powder and 
conformed by rapid prototyping with PVA.  
SAMPLE 
SBET 
(m2·g-1) 
Vp 
(cm3·g-1) 
Dp 
(nm) 
% 
PVA* 
% 
LEV* 
% 
VAN* 
% 
RIF** 
Powder MGHA 178.0 0.35 8.5 - - -  
MG-PVA 145.5 0.30 8.7 20.6 - -  
MGLEV-PVAVAN 27.6 0.05 4.5 19.0 3 1.8 - 
GRIF-MGLEV-PVAVAN 19.4 0.04 7 23.1 3 1.8 2.5 
(*) Determined by elemental analyses of Table S1; (**) Determined by combination 
of TG study and indirect method.  
 
 
Table 2: Release kinetic parameters of rifampin, levofloxacin and vancomyci delivery 
from different matrices 
Drug 
release 
∆G (x10-21J) KS 
(h-1) 
Koff 
(h-1) 
 
LEV 1.7 0.13 0.0006 GRIF-MGLEV-PVAVAN 
LEV 1.9 0.14 0.0005 MGLEV-PVAVAN 
LEV 1.8 0.14 0.0006 MGLEV-PVA 
VAN 7.5 0.02 0.89816 GRIF-MGLEV-PVAVAN 
VAN 8.0 0.017 0.87937 MGLEV-PVAVAN 
VAN 7.4 0.019 0.86973 MG-PVAVAN 
RIF 4.2 29.285 3.02853 GRIF-MGLEV-PVAVAN 
RIF 4.1 29.328 3.01777 MGLEV-PVAVAN 
RIF 4.1 28.358 3.02842 MG-PVAVAN 
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Figure and Figure captions 
 
Fig.1 Schematic design of the present study based on the development of a novel 
therapeutic multidrug 3D scaffolds for bone infection. These 3D scaffolds containing 
rifampin, levofloxacin and vancomycin, is formed by a mixture of MGHA and PVA 
processed rapid prototyping technique (MGLEVPVAVAN) and posterior coating with 
gelatin-glutaraldehyde layer (GRIFMGLEVPVAVAN). (Left) schematic representation of 
the localization of different antibiotics in different compartment of 3D scaffold to obtain 
a sequential and effective release kinetics of multi-therapy. (Right) Processing of 
fabrication of these multifunctional 3D scaffolds for bone infection therapy.  
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Fig.2 XRD patterns corresponding to low (left) and wide (right) scattering angles. 
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Fig.3 Morphological and structural characterization 3D composite scaffolds 
MGLEVPVAVAN showing a high a regular level of hierarchical porosity from macro to 
mesoporous scale. (A, B, C and D) SEM micrographs at different magnification. (E) 
TEM image and FT diagram showing the mesoporous arrangement in a 2D hexagonal 
structure.  
 
 
Fig.4 SEM micrographs at different magnification corresponding to 
GRIFMGLEVPVAVAN 3D scaffold.  
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Fig.5 In vitro degradability assay in SBF corresponding to GRIFMGLEVPVAVAN 3D 
scaffold. SEM images at different magnification showing the surface of the 3D 
scaffolds, after 1 h, 15 and 30 days of incubation in SBF. 
 
 
Fig.6 TEM images of GRIFMGLEVPVAVAN after 7 days in SBF. Needle-shaped 
crystallites are observed together with mesoporous channels of the scaffolds. High-
magnification image evidence ordered planes corresponding to (211) and (002) d-
spacings of an apatite phase. EDS analyses shows that needle-shaped is Ca-deficient 
apatite with a Ca/P ratio of 1.60. 
 
  
31 
 
 
 
Fig.7 Graphic representation of the RIF, LEV and VAN release kinetics fitting to the 
model corresponding to eq. 1. 
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Fig.8  Antimicrobial activity of both 3D MGLEVPVAVAN (containing LEV and VAN) 
and GRIFMGLEVPVAVAN (containing RIF, LEV and VAN) scaffolds onto preformed S. 
aureus biofilm. The confocal images show clear differences between both 3D scaffolds 
with and without RIF. For 3D MGLEVPVAVAN scaffolds, still appear small fragments of 
biofilm of size of 20-30 µm, which are formed by lived bacteria (green) covered by 
matrix biofilm layer (blue) after 24 h. For 3D GRIFMGLEVPVAVAN scaffolds, it is 
evident their rapid antimicrobial effect, showing the total destruction of biofilm, 
appearing all dead bacteria (red) after 1 h and a few scattering formed by small 
fragments of protective biolayer (blue), dead bacteria (red) and small amount of live 
bacteria (green) after 24 h. 
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Fig.9 Confocal microscopy study concerning to antimicrobial activity of 
GRIFMGLEVPVAVAN (containing RIF, LEV and VAN) scaffolds onto Gram-negative E. 
coli (EC) biofilm. The confocal images show the initial biofilm preformed on covered 
glass-disk and after 1, 6 and 24 h of incubation with the 3D multidrug 
GRIFMGLEVPVAVAN sample.  
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Fig.10 Histograms showing the Log[CFU] from Gram-positive (S. aureus) and Gram-
negative (E. coli) biofilms, respectively before and after incubation different times with 
both 3D MGLEVPVAVAN and GRIFMGLEVPVAVAN scaffolds. 
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Fig.11 Preliminary in vitro biocompatibility assays: (A) Cytotoxicity by lactate 
dehydrogenase (LDH) released into the medium after 1 day of incubation; (B) 
Proliferation assays in terms of mitochondrial activity (MTT) after 7 days incubation 
and (C) Differentiation assays in term of alkaline phosphatase activity (ALP) after 7 
days of incubation of MC3T3-E1 preosteoblastic cells cultured onto 
GRIFMGLEVPVAVAN scaffolds. The values shown are means ± standard errors of a 
representative of three similar experiments carried out in duplicate. Differences between 
substrates at a given time point are not significant (p < 0.05, two-way ANOVA multiple 
comparison unless denoted by an asterisk (*).   
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Fig.12 Mineralization in vitro assays of MC3T3-E1 preosteoblastic cells cultured after 
10 days of incubation with 3D GRIFMGLEVPVAVAN scaffolds. (Top) Alizarin assays 
measured in the well base showing no significant differences with the control. (Bottom) 
Surface characterization with XRD with and also without presence of preosteoblast cells 
XRD of 3D GRIFMGLEVPVAVAN scaffolds.  Differences between substrates at a given 
time point are not significant (p < 0.05, two-way ANOVA multiple comparison unless 
denoted by an asterisk (*).   
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Fig.13 (A) SEM micrograph and (B) Confocal image, showing the actin stained with 
Atto 565-conjugated phalloidin (red) and nuclei stained with DAPI (blue) of MC3T3-E1 
preosteoblastic cells cultured on GELRIFMGHALEVOPVAVAN scaffold (reflected in 
green) after 7 days of incubation. 
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Supporting information: 
Table S1: Elemental analyses data showing the percent of carbon, hydrogen and 
nitrogen of each table  
Sample  %C %H %N 
VAN* 43.85 5.64 7.06 
LEV* 58.36 5.56 11.31 
MG Powder 0.19 0.29 0.06 
MGPVA 10.66 2.38 0.09 
MGLEVPVA 10.37 2.16 0.34 
MGPVAVAN 12.18 2.53 0.13 
MGLEVPVAVAN 10.27 2.07 0.47 
*Commercial drug powder from Sigma-Aldrich  
 
 
Fig.S1 SEM study corresponding to MGLEVPVAVAN scaffolds. Left shows different 
magnifications of the surface. Right shows the cross section view at different 
magnification.  
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Fig.S2 Variation of calcium concentration versus time when the GRIFMGLEVPVAVAN 
scaffolds in SBF showing a short increase of calcium followed to a notable decreasing. 
Note that the SBF was removed each 3 days. 
 
Fig.S3 Dosage of each antimicrobial agent after 1, 6 and 24 h.  
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Fig.S4 Long time in vitro of biocompatibility assays by incubation of 
GRIFMGLEVPVAVAN scaffolds on MC3T3-E1 preosteoblastic cells cultured. Lactate 
dehydrogenase (LDH) determination after 7 days of incubation. Mitochondrial activity 
(MTT) after 15 days incubation and alkaline phosphatase activity (ALP) after 15 days 
of incubation. Not significant differences are shown.  
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Statement of Significance 
The present study is focused in finding an adequate therapeutic solution for the 
treatment of bone infection based on 3D multifunctional scaffolds, which 
combines the merits of osseous regeneration and local multidrug delivery. These 
3D multidrug scaffolds, containing rifampin, levofloxacin and vancomycin, 
localized in different compartments to achieve different release kinetics. These 
3D multidrug scaffolds displays an early and fast release of rifampin followed 
by sustained and prolonged release of vancomycin and levofloxacin, which are 
able to destroy Staphylococcus and Escherichia biofilms as well as inhibit 
bacteria growth in very short time periods. This new combined therapy approach 
involving the sequential delivery of antibiofilms with antibiotics constitutes an 
excellent and promising alternative for bone infection treatment. 
 
